Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSV: TELO )

0.1550 UNCHANGED
Streaming Delayed Price Updated: 2:13 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1550
Bid (Size) 0.1400 (160)
Ask (Size) 0.1650 (5)
Prev. Close 0.1550
Today's Range 0.1550 - 0.1550
52wk Range 0.1050 - 0.2750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
Toronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce... 
Via Newsfile

Performance

YTD
-18.42%
-18.42%
1 Month
-29.55%
-29.55%
3 Month
-16.22%
-16.22%
6 Month
+34.78%
+34.78%
1 Year
-35.42%
-35.42%

More News

Read More
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Via FinancialNewsMedia
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
Via Newsfile
Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Telo Genomics Participates in the 18th International Myeloma Society Workshop 2021
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Telo Genomics Engages Clinical and Regulatory Affairs Veteran to Lead the Company's ISO 15189 Certification & CLIA Laboratory Accreditation Undertaking
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Telo Genomics Completes First Tranche of Oversubscribed Private Placement
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma Patients
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.